82 related articles for article (PubMed ID: 16968570)
1. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
Kasper LH; Everitt D; Leist TP; Ryan KA; Mascelli MA; Johnson K; Raychaudhuri A; Vollmer T;
Curr Med Res Opin; 2006 Sep; 22(9):1671-8. PubMed ID: 16968570
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
3. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
[TBL] [Abstract][Full Text] [Related]
4. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
6. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Gottlieb AB; Cooper KD; McCormick TS; Toichi E; Everitt DE; Frederick B; Zhu Y; Pendley CE; Graham MA; Mascelli MA
Curr Med Res Opin; 2007 May; 23(5):1081-92. PubMed ID: 17519075
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.
Subramanian GM; Cronin PW; Poley G; Weinstein A; Stoughton SM; Zhong J; Ou Y; Zmuda JF; Osborn BL; Freimuth WW
Clin Infect Dis; 2005 Jul; 41(1):12-20. PubMed ID: 15937757
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.
Bissonnette R; Papp K; Maari C; Yao Y; Robbie G; White WI; Le C; White B
J Am Acad Dermatol; 2010 Mar; 62(3):427-36. PubMed ID: 20159310
[TBL] [Abstract][Full Text] [Related]
10. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
12. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.
Bowen JD; Petersdorf SH; Richards TL; Maravilla KR; Dale DC; Price TH; St John TP; Yu AS
Clin Pharmacol Ther; 1998 Sep; 64(3):339-46. PubMed ID: 9757158
[TBL] [Abstract][Full Text] [Related]
16. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
17. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
19. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Curtin F; Lang AB; Perron H; Laumonier M; Vidal V; Porchet HC; Hartung HP
Clin Ther; 2012 Dec; 34(12):2268-78. PubMed ID: 23200102
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
